CSIMarket
 

Utah Medical Products Inc  (UTMD)
Other Ticker:  
 

Utah Medical Products Inc's Working Capital Per Sales

UTMD's Working Capital and Revenue growth



UTMD Working Capital Per Revenue (Dec 31 2023)
IV. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Working Capital Change 30.25 % 25.7 % 21.33 % 20.96 % 10.08 %
Y / Y Revenue Change -8.73 % -5.13 % 1.6 % 5.12 % 3.05 %
Working Capital Per Revenue 1.82 1.66 1.55 1.48 1.43
Total Ranking # 1971 # # 2959 # 2978 # 3375
Seq. Working Capital Change 8.43 % 5.19 % 6.05 % 7.68 % 4.64 %
Seq. Revenue Change -7.18 % 1.75 % -7.77 % 4.79 % -3.52 %





Comment on UTMD's Working Capital Per Revenue in the fourth quarter 2023
Utah Medical Products Inc's Working Capital Per Revenue sequentially grew to 1.82 during the Q4 2023, a new company high. Due to increase of revenue in the Q4 2023 year on year by -8.73%.

Within Healthcare sector 32 other companies have achieved lower Working Capital Per Revenue during the Q4 2023. While Working Capital Per Revenue total ranking has deteriorated in the fourth quarter 2023, compared to previous quarter from to 1971.
Working Capital Per Revenue Ranking
Within: No.
Industry # 6
Sector # 33
S&P 500 # 1971


Working Capital Per Revenue Statistics
High Average Low
1.82
1.01
0.36
(Dec 31 2023)   (Dec. 30, 2013)



Financial Statements
Utah Medical Products Inc's Working Capital $ 102 Millions Visit UTMD's Balance sheet
Utah Medical Products Inc's Revenues $ 12 Millions Visit UTMD's Income Statement
Where are UTMD's Sales coming from? Visit UTMD's Sales by Geography




Companies with similar Average Working Capital Per Revenue for 12 months ending Dec 31 2023, within Healthcare Sector Working Capital Per Revenue
Maxcyte inc   4.98 
Profound Medical Corp   4.94 
Soligenix inc   4.73 
Arcutis Biotherapeutics Inc   4.72 
Cara Therapeutics inc   4.69 
Biontech Se  4.57 
Zymeworks Inc   4.42 
Liquidia Corporation  4.41 
Meiragtx Holdings Plc  4.36 
Legend Biotech Corporation  4.24 
Marker Therapeutics inc   4.19 
Neurometrix Inc   4.13 
Editas Medicine Inc   3.94 
Macrogenics Inc   3.78 
Aclaris Therapeutics Inc   3.76 
Butterfly Network inc   3.55 
Pacific Biosciences Of California Inc   3.41 
Xencor Inc  3.22 
Travere Therapeutics Inc   3.21 
Zai Lab Limited  3.19 
Alpine Immune Sciences Inc   3.10 
Quanterix Corp  2.84 
Nurix Therapeutics Inc   2.78 
Igc Pharma Inc   2.71 
Cvrx inc  2.66 
Blueprint Medicines Corporation  2.58 
Ionis Pharmaceuticals Inc  2.57 
Omniab Inc   2.52 
2seventy Bio Inc   2.41 
Adaptimmune Therapeutics Plc  2.32 
Date modified: 2024-03-26T21:06:17+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com